Valuation : Abbott Laboratories (Pakistan) Limited

Market Cap 90.64B 327M 281M 264M 241M 452M 30.92B 453M 3.14B 1.21B 15.84B 1.23B 1.2B 50.44B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 90.64B 327M 281M 264M 241M 452M 30.92B 453M 3.14B 1.21B 15.84B 1.23B 1.2B 50.44B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day-1.58%
1 week-4.71%
Current month-1.53%
1 month-0.92%
3 months+4.06%
6 months+1.34%
Current year-11.83%
1 week 907
Extreme 907
960
1 month 890.08
Extreme 890.08
979.9
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Chairman - 30/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.58%-4.71%-22.25%+157.19% 332M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.95%-1.42%+28.96%+40.10% 352B
-3.18%+1.39%+20.66%+43.86% 304B
+0.30%+0.60%-0.40%+13.54% 252B
-1.55%+1.11%+54.15%+75.59% 236B
+0.02%+1.17%-14.59%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -1.04%+0.97%+23.07%+63.43% 367.87B
Weighted average by Cap. -1.04%+0.62%+37.20%+67.52%

Financials

2024 2025
Net sales 68.18B 246M 211M 199M 182M 340M 23.26B 341M 2.36B 912M 11.91B 924M 903M 37.94B 75.4B 272M 234M 220M 201M 376M 25.72B 377M 2.61B 1.01B 13.17B 1.02B 999M 41.96B
Net income 5.23B 18.88M 16.24M 15.27M 13.94M 26.07M 1.79B 26.16M 181M 69.99M 914M 70.9M 69.35M 2.91B 7.97B 28.74M 24.71M 23.24M 21.22M 39.68M 2.72B 39.81M 276M 107M 1.39B 108M 106M 4.43B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
07/09/26 PKR 925.87 -1.58% 14,910
04/09/26 PKR 940.73 +0.52% 16,833
03/09/26 PKR 935.86 +0.59% 22,056
02/09/26 PKR 930.39 -1.23% 13,677
01/09/26 PKR 941.94 +0.18% 155,484
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
925.87
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABOT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!